OUR RESEARCH DIRECTION

Offering new therapeutic possibilities through vascular normalization

Through its distinctive approach to vascular normalization, Curacle offers new therapeutic possibilities for intractable and age-related diseases while expanding its research across vascular-related diseases, with retinal, kidney and thrombotic diseases at the core.

Retinal diseases

Pursuing vision protection through vascular stabilization and functional restoration

Kidney diseases

Pursuing kidney function preservation through vascular protection and modulation of inflammation and fibrosis

Thrombotic & ischemic diseases

An antithrombotic approach pursuing bleeding risk minimization and vascular protection

Main Pipelines

Pipeline Modality Target Indication Development Status Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU06
(Rivasterat) 		PO Endothelial Dysfunction Blocker Diabetic Macular Edema / Age-related Macular Degeneration Completed Phase 2a clinical trial in the U.S. (Q1 2024)
CU01 PO NRF2 / TGF-β Diabetic Nephropathy Completed Phase 2b clinical trial in Korea (Q1 2026)
MT-101 IV (mAb) Tie2 Acute Kidney Injury/ Chronic Kidney Disease Preclinical studies in progress
MT-103
(MMT-205) 		IV (BsAb) Tie2 / VEGF Diabetic Macular Edema / Age-related Macular Degeneration Global licensing to Memento Medicines (May 2026).
Preclinical studies in progress
MT-201 IV (mAb) PDI Thrombotic Diseases Preclinical studies in progress
MT-202 IV (BsAb) PDI / Tie2 Thrombotic Diseases Preclinical studies in progress

Emerging Pipelines

Pipeline Modality Target Indication Development Status Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Partner
CU71 PO Endothelial Dysfunction Blocker Neurodegenerative Disease Discovery
CU72 PO Undisclosed Idiopathic Pulmonary Fibrosis Discovery
CU73 PO Undisclosed Thrombotic Diseases Discovery
CU03 PO Multi Target Age-related Macular Degeneration Completed Phase 2a clinical trial in Korea (Q1 2022)
CU104 PO Indication expansion of CU06 Ulcerative Colitis Phase 2a IND approvals in the U.S. and Europe
Development strategy under review in alignment with CU06 global partnering
CU106 PO Indication expansion of CU06 Immuno-Oncology Combination Phase 1 completed in the U.S.
Development strategy under review in alignment with CU06 global partnering
MT-105 IV Undisclosed Inflammatory Bowel Disease Discovery
MT-40X IV Undisclosed Cancer Discovery
MT-501 IV (BsAb) Tie2 / C5 axis Vasculitis Discovery
CP01 PO Endothelial Dysfunction Blocker Canine Chronic Kidney Disease Phase 3 clinical trial in dogs ongoing (Korea)
CP02 PO Endothelial Dysfunction Blocker Feline Chronic Kidney Disease Preclinical studies in progress